drugset / Trial / NCT05833906
Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects
RandomizedParallel-groupSingle-blindScreening
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of CKR-051 in healthy participants. This study aiming to develop an agent for skin regeneration; potential treatments include acute and chronic wounds (c.f. Diabetic foot ulcers).
Timeline
- Start
- 2023-04-25
- Primary completion
- 2024-01-08
- Completion
- 2024-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKR-051 | Unknown | 5 g | Other |
| Subject | CKR-051 | Unknown | 10 g | Other |
Indications
No indication recorded.